Last reviewed · How we verify
Topical Antimicrobial/Antifungal Medications
Topical antimicrobial and antifungal medications work by disrupting microbial cell membranes, inhibiting fungal cell wall synthesis, or interfering with microbial protein synthesis to eliminate or inhibit growth of bacteria and fungi on skin surfaces.
Topical antimicrobial and antifungal medications work by disrupting microbial cell membranes, inhibiting fungal cell wall synthesis, or interfering with microbial protein synthesis to eliminate or inhibit growth of bacteria and fungi on skin surfaces. Used for Fungal skin infections (e.g., tinea pedis, tinea corporis, candidiasis), Bacterial skin infections, Mixed microbial skin infections.
At a glance
| Generic name | Topical Antimicrobial/Antifungal Medications |
|---|---|
| Also known as | Bacitracin; Amphotericin B; others noted below. |
| Sponsor | Mylan Inc. |
| Drug class | Topical antimicrobial/antifungal agents (multiple classes) |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This category encompasses multiple drug classes with varying mechanisms. Common approaches include disruption of bacterial cell membranes (e.g., quaternary ammonium compounds), inhibition of fungal ergosterol synthesis (e.g., azoles), disruption of fungal cell wall β-glucan formation (e.g., echinocandins), or broad-spectrum antimicrobial activity through oxidative stress or metal ion mechanisms. These agents are applied directly to affected skin areas to achieve high local concentrations while minimizing systemic exposure.
Approved indications
- Fungal skin infections (e.g., tinea pedis, tinea corporis, candidiasis)
- Bacterial skin infections
- Mixed microbial skin infections
Common side effects
- Local irritation or burning
- Pruritus
- Erythema
- Contact dermatitis
Key clinical trials
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- The Role of Adjuvant Corneal Crosslinking in the Management of Infective Keratitis (EARLY_PHASE1)
- The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
- Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers (PHASE2, PHASE3)
- Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical Antimicrobial/Antifungal Medications CI brief — competitive landscape report
- Topical Antimicrobial/Antifungal Medications updates RSS · CI watch RSS
- Mylan Inc. portfolio CI